Last reviewed · How we verify
insulin human (HR1799)
Insulin human (HR1799) is a recombinant human insulin that binds to insulin receptors on cells to promote glucose uptake and regulate blood glucose levels.
Insulin human (HR1799) is a recombinant human insulin that binds to insulin receptors on cells to promote glucose uptake and regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | insulin human (HR1799) |
|---|---|
| Also known as | Insuman Basal / Insuman Comb / Insuman Rapid |
| Sponsor | Sanofi |
| Drug class | Insulin (human recombinant) |
| Target | Insulin receptor (INSR) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a biosynthetic human insulin produced via recombinant DNA technology. It mimics endogenous insulin by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. HR1799 is Sanofi's formulation of human insulin for parenteral administration in diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes (PHASE3)
- Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes (PHASE4)
- Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy (PHASE3)
- Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin human (HR1799) CI brief — competitive landscape report
- insulin human (HR1799) updates RSS · CI watch RSS
- Sanofi portfolio CI